A number of studies suggested that RIG-I acts as a tumour suppressor in hepatocellular carcinoma (HCC), acute myeloid leukaemia (AML), and cervical cancer [42,43,44,45,46,47]. Here, RIGI is linked to acute myeloid leukemia.